Further analysis of the relationship between CRGs and the prognosis of gliomas revealed that high expression of FDX1, DLD, DLAT, and LIPT1 was associated with poorer survival in glioma patients, and high expression of CDKN2A and PDHA1 was significantly associated with better survival in gliomas. Here, CDKN2A is linked to central nervous system cancer.